Evaluation Of Platelet Aggregation Activity Depending on The Duration of Antiplatelet Administration in Patients with Coronary Heart Disease

Authors

  • Khodzhanova Shakhnoza Iskandarovna

DOI:

https://doi.org/10.47750/pnr.2022.13.S09.086

Keywords:

acetylsalicylic acid; coronary heart disease; spontaneous platelet aggregation, ADP-induced platelet aggregation, aspirin resistance.

Abstract

To study the aggregation activity of platelets in patients with ischemic heart disease depending on the long-term intake of acetylsalicylic acid (ASA). Material and methods. The study included: 116 patients with coronary artery disease with stable angina pectoris, taking a standard dose of aspirin 75 mg/day. during various terms. Patients with SSN were divided into 4 groups according to the duration of taking ASA. Platelet aggregation was measured using a laser platelet aggregation analyzer Alat-2 Biol, with computer processing according to the AGGR program. Adenosine diphosphate (ADP) in concentrations of 0.1, 1.0, 5.0 mmol/l was used as an inductor. The results of the study of patients taking ASA for more than 5 years showed that spontaneous aggregation and ADP-induced platelet aggregation were higher than in patients taking the drug for less than 5 years. Statistically significant differences were observed when compared with a group of patients taking ASA for less than a year (spontaneous aggregation of 1.7±0.09 (p<0.05), 0.1 μm ADP-induced aggregation of 6.58±0.86 (p<0.05), 1.0 μm ADP-induced aggregation of 16.51±1.63 (p<0.01), 5.0 μm ADP-induced aggregation 58.44±3.72 (p<0.01). Conclusion. Thus, the results showed that with an increase in the duration of aspirin intake, there was a change in both spontaneous and ADP-induced platelet aggregation with a statistically significant increase.

Downloads

Published

2022-11-12

How to Cite

Khodzhanova Shakhnoza Iskandarovna. (2022). Evaluation Of Platelet Aggregation Activity Depending on The Duration of Antiplatelet Administration in Patients with Coronary Heart Disease. Journal of Pharmaceutical Negative Results, 754–760. https://doi.org/10.47750/pnr.2022.13.S09.086

Issue

Section

Articles